STOCK TITAN

IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

IN8bio (INAB) reported final Phase 1/2 glioblastoma results showing median overall survival of 20.9 months among patients receiving repeat-dose gamma-delta T cells. Across INB-200 and INB-400, median overall survival was 59% higher than the standard-of-care control group's 13.2 months. Median progression-free survival—time without disease worsening—was 13.0 versus 6.6 months. Two-year survival was 50% (7 of 14) versus 10% (1 of 10).

The analysis included 17 treated patients, with data as of October 30, 2026, and was presented November 14 at SNO. Total surgical resection occurred in 43% of repeat-dose patients versus 80% of controls. With up to six repeat doses, no cytokine release syndrome, immune-related neurotoxicity, major infections or treatment-related serious adverse events were observed; no treatment-related deaths were reported. Early trial results do not establish future outcomes.

Loading...
Loading translation...
6 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointRepeat-dose median overall survival reached 20.9 months, versus 13.2 months with standard care, a 59% increase.
  • Moderate pointRepeat-dose median progression-free survival reached 13.0 months, versus 6.6 months with standard care, a 97% increase.
  • Moderate pointSafety through up to six repeat doses showed no observed cytokine release syndrome, immune-related neurotoxicity or major infections.
  • Minor pointRepeat-dose two-year survival was 50% (7 of 14), versus 10% (1 of 10) with standard care.
  • Minor pointTreatment-related serious adverse events and deaths were not reported.
  • Minor pointINB-200 DL1 median progression-free/overall survival was 8.0/15.7 months versus controls' 6.6/13.2; two-year survival was 0/3 versus 1/10.

Negative

  • Minor pointTwo INB-200 repeat-dose patients died from cardiovascular events without disease progression.

Key Figures

Median overall survival: 20.9 months Median progression-free survival: 13.0 months Alive at two years: 50% (7 of 14) +1 more
Median overall survival
20.9 months
Repeat-dose patients; 13.2 months in SOC group
Median progression-free survival
13.0 months
Repeat-dose patients; 6.6 months in SOC group
Alive at two years
50% (7 of 14)
Repeat-dose patients; compared with 10% (1 of 10) in SOC group
Patients analyzed
17 patients
INB-200 or INB-400 studies

Historical Context

1 past event · Latest: Aug 06
1 event
  1. Aug 06

    Glioblastoma data

    24h Move
    +0.0%

    Earlier update reported 13.0-month mPFS and OS above 19.5 months versus SOC.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

mos, mpfs, cytokine release syndrome, icans
4 terms
mos medical
"Median overall survival (mOS) of 20.9 months in repeat-dose patients"
mos is a common abbreviation for months, used to indicate a time span in financial statements, forecasts, contracts, or trial timelines. Timeframes matter to investors because they show how long cash, obligations, or expected results will play out—similar to seeing how many months your household budget must cover expenses, it helps assess risk, liquidity, and when returns or obligations are likely to occur.
mpfs medical
"Median progression-free survival (mPFS) of 13.0 months"
The MPFS (Medicare Physician Fee Schedule) is the official price list Medicare uses to set how much it will pay doctors and other clinicians for specific medical services. Think of it like a menu of reimbursement rates: changes to the MPFS raise or lower what providers earn for each procedure, which can directly affect health-care providers’ revenue, profit margins and the valuations of companies that rely heavily on Medicare payments — information investors use to judge financial risk and growth prospects.
cytokine release syndrome medical
"no observed cytokine release syndrome (CRS), ICANS"
An intense immune overreaction in which the body's defense system releases a large surge of signaling proteins, causing fever, low blood pressure, breathing trouble or organ stress; imagine the immune system's alarm going into overdrive and flooding the body with emergency responders. Investors care because this side effect can slow or block regulatory approval, increase clinical trial costs and liabilities, limit how widely a therapy can be used, and therefore affect a drug's market value and sales potential.
icans medical
"immune effector cell-associated neurotoxicity syndrome (ICANS)"
ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) is a range of brain-related side effects that can occur after certain immune-cell cancer therapies, such as CAR-T. Symptoms can include confusion, speech problems, seizures or reduced consciousness, and they are caused by an overactive immune response affecting the brain. Investors care because ICANS can influence patient safety, trial outcomes, regulatory approvals, treatment labeling and adoption, all of which affect a therapy’s commercial prospects and development costs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC)

50% of repeat-dose patients remained alive at two years, compared to 10% in the SOC control group

Median progression-free survival (mPFS) of 13.0 months, nearly doubled the 6.6 months observed in the SOC control group

Favorable safety profile with no observed cytokine release syndrome (CRS), ICANS, major infections or treatment-related serious adverse events with up to six repeat doses of gamma-delta T cells

NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced updated clinical data from its INB-200 and INB-400 programs in newly diagnosed glioblastoma (GBM), presented in an oral session at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia.

The updated results demonstrated consistent survival outcomes among patients receiving repeat doses of IN8bio’s drug-resistant γδ T cells. Across the INB-200 and INB-400 studies, patients receiving repeat doses of therapy achieved a final mOS of 20.9 months (+59%) and mPFS of 13.0 months (+97%), compared to 13.2 months and 6.6 months, respectively, in those receiving the SOC. Notably, 50% of patients receiving repeat-dose therapy (7 of 14) were alive at two years, compared with 10% of patients (1 of 10) in the group receiving only SOC. These outcomes were observed despite a lower proportion of repeat-dose patients having undergone total surgical resection.

Importantly, γδ T cell therapy demonstrated a favorable safety and tolerability profile across the clinical studies, with no observed CRS, immune effector cell-associated neurotoxicity syndrome (ICANS), major infections or treatment-related serious adverse events. No treatment-related deaths were reported.

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence of γδ T cells in patients receiving multiple doses. Importantly, across our clinical experience, we have not observed any CRS, ICANS, major infections or treatment-related serious adverse events. These data continue to underscore the potential of γδ T cell-based therapies to provide meaningful clinical benefit for patients.”

Updated Clinical Results Presented at SNO 2026

The results were presented on Saturday, November 14, 2026 during the Clinical Trials Oral Abstracts Session II of the Society for Neuro-Oncology Annual Meeting in a presentation titled, “INB-200/400: Final Phase 1/2 Study Results and A.I. based Deep Correlative Analysis of Gene-Modified Autologous Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma (GBM) Patients.”

The analysis included 17 patients treated with INB-200 or INB-400 across four leading cancer centers: the University of Alabama at Birmingham (UAB) O’Neal Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Moffitt Cancer Center and the Cleveland Clinic.

Treatment ArmMedian PFS
(months)
Median OS
(months)
Patients Alive at
Two Years (%)
Historical NEJM Data6.914.626.5%
Control (SOC) Patients6.613.2(1/10) 10%
INB-200 DL1 Patients8.015.7(0/3) 0%
INB-200 Repeat Dose Patients16.121.1(5/10)* 50%
INB-400 Repeat Dose Patients13.020.9(2/4) 50%
All Repeat Dose Patients13.020.9(7/14) 50%

Note: As of October 30, 2026. *Patients 007 and 014 passed away from cardiovascular events without progression. Patients without progression who are no longer alive are not censored in this analysis. Early trial results are not indicative of future results, including the outcome of this trial.

Total surgical resection was performed in 43% of repeat-dose patients, compared with 80% of SOC control patients.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also developing INB-100, an allogeneic γδ T cell therapy candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell therapy candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.in8bio.com.

Investors and Corporate Contact:

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@in8bio.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What survival results did IN8bio report for repeat-dose INB-200 and INB-400 in glioblastoma?

Repeat-dose patients had 20.9 months median overall survival, compared with 13.2 months for standard-of-care controls. Median progression-free survival was 13.0 versus 6.6 months, and two-year survival was 50% (7 of 14) versus 10% (1 of 10).

How did IN8bio handle deaths without progression in its glioblastoma analysis?

Patients who died without disease progression were not censored, meaning they were not excluded from subsequent analysis on that basis. Two INB-200 repeat-dose patients died from cardiovascular events without progression.

Keep reading